Citation metadata

Date: May 2022
From: Oncology(Vol. 36, Issue 5)
Publisher: Intellisphere, LLC
Document Type: Article
Length: 878 words
Lexile Measure: 1340L

Document controls

Main content

Article Preview :

Product Profile

Drug name:

Dostarlimab CJemperli]

Date of approval:

August 17, 2021

Initial indication:

For adult patients with recurrent or advanced solid tumors with deficient mismatch repair CdMMFQ, as determined by an FDAapproved test, who have progressed on or following prior treatment and have no other treatment options (1)

Dosage and administration:

500 mg every 3 weeks for doses 1 to 4, with subsequent dosing starting 3 weeks after dose 4 at 1000 mg every 6 weeks

How supplied:

Intravenously over 30 minutes

Pivotal clinical trial:

Phase 1 GARNET trial CNCT02715284), cohorts A1 and P

Megan May, PharmD, BCOP

Clinical Oncology Pharmacy Specialist Baptist Health Lexington Lexington, Kentucky

ONCOLOGY[R]: Can you describe the mechanism of action of dostarlimab?

MAY: Dostarlimab is a PD-1 antibody. It is a humanized monoclonal antibody of the IgG4 isotype that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2.This causes a release in the PD-1 pathway through mediated inhibition of the immune response.

QWhat are some of the * biggest concerns with dostarlimab's toxicity profile and have any become more apparent in the real-world setting? MAY: In the real world, dostarlimab has been well tolerated. However, there are some significant immune-related adverse effects that do occur. We need to keep these in mind. When we're counseling patients prior to the start...

Source Citation

Source Citation   

Gale Document Number: GALE|A704419382